Cargando…

Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses

BACKGROUND: PALETTE is a phase 3 trial that demonstrated single-agent activity of pazopanib in advanced soft tissue sarcomas (aSTS). We performed retrospective subgroup analyses to explore potential relationships between patient characteristics, prior lines of therapy, dose intensity, and dose modif...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cesne, Axel Le, Bauer, Sebastian, Demetri, George D., Han, Guangyang, Dezzani, Luca, Ahmad, Qasim, Blay, Jean-Yves, Judson, Ian, Schöffski, Patrick, Aglietta, Massimo, Hohenberger, Peter, Gelderblom, Hans
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691522/ https://www.ncbi.nlm.nih.gov/pubmed/31409302 http://dx.doi.org/10.1186/s12885-019-5988-3

Ejemplares similares

Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study
por: Sleijfer, S, et al.
Publicado: (2012)

Retrospective quality control review of FDG scans in the imaging sub-study of PALETTE EORTC 62072/VEG110727: a randomized, double-blind, placebo-controlled phase III trial
por: Hristova, Ivalina, et al.
Publicado: (2015)

Survival of soft tissue sarcoma patients after completing six cycles of first-line anthracycline containing treatment: an EORTC-STBSG database study
por: Verschoor, Arie Jan, et al.
Publicado: (2020)

Pazopanib for the treatment of soft-tissue sarcoma
por: Heudel, Pierre, et al.
Publicado: (2012)

Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first‐line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer‐Soft Tissue and Bone Sarcoma Group (EORTC‐STBSG)
por: Lindner, Lars H., et al.
Publicado: (2018)

The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib
por: Wilding, Christopher P, et al.
Publicado: (2019)

Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma The European Organisation for Research and Treatment of Cancer – Soft Tissue and Bone Sarcoma Group (STBSG) and French Sarcoma Group (FSG) study
por: Penel, N, et al.
Publicado: (2011)

Histopathological and Molecular Profiling of Clear Cell Sarcoma and Correlation with Response to Crizotinib: An Exploratory Study Related to EORTC 90101 “CREATE” Trial
por: Lee, Che-Jui, et al.
Publicado: (2021)

Tension Pneumothorax: Is it Sarcoma or Pazopanib?
por: Sebanayagam, Vinoja, et al.
Publicado: (2020)

Chromatic palette
por: Farlow, Tal
Publicado: (1981)

Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials
por: Cesne, A L, et al.
Publicado: (2013)

Pazopanib: Approval for Soft-Tissue Sarcoma
por: Nguyen, Diana T., et al.
Publicado: (2013)

Pazopanib in advanced soft tissue sarcomas
por: Lee, Alex T. J., et al.
Publicado: (2019)

iCREATE: imaging features of primary and metastatic alveolar soft part sarcoma from the EORTC CREATE study
por: Mcaddy, Naami Charlotte, et al.
Publicado: (2020)

A palette of particles
por: Bernstein, Jeremy
Publicado: (2013)

Pregnancy in Women with Metastatic Sarcomas
por: Yazigi, Alexandre, et al.
Publicado: (2020)

Prognostic Significance of Bone Metastasis in Soft Tissue Sarcoma Patients Receiving Palliative Systemic Therapy: An Explorative, Retrospective Pooled Analysis of the EORTC-Soft Tissue and Bone Sarcoma Group (STBSG) Database
por: Kantidakis, Georgios, et al.
Publicado: (2022)

Pneumothorax as adverse event in patients with lung metastases of soft tissue sarcoma treated with pazopanib: a single reference centre case series
por: Verschoor, Arie J, et al.
Publicado: (2014)

Pazopanib radio-sensitization of human sarcoma tumors
por: Wang, Feng, et al.
Publicado: (2018)

Pazopanib in the management of advanced soft tissue sarcomas
por: Cranmer, Lee D, et al.
Publicado: (2016)

Pazopanib in the Treatment of Bone Sarcomas: Clinical Experience()
por: Aggerholm-Pedersen, Ninna, et al.
Publicado: (2019)

Expanding the Palette of Phenanthridinium Cations
por: Cairns, Andrew G, et al.
Publicado: (2014)

Correlation of Immunological and Molecular Profiles with Response to Crizotinib in Alveolar Soft Part Sarcoma: An Exploratory Study Related to the EORTC 90101 “CREATE” Trial
por: Lee, Che-Jui, et al.
Publicado: (2022)

Intra-Tumoral Pharmacokinetics of Pazopanib in Combination with Radiotherapy in Patients with Non-Metastatic Soft-Tissue Sarcoma
por: Molenaar-Kuijsten, Laura, et al.
Publicado: (2021)

Clinical Activity of Pazopanib in Metastatic Extraosseous Ewing Sarcoma
por: Attia, Steven, et al.
Publicado: (2015)

The Successful Treatment of Metastatic Extraosseous Ewing Sarcoma with Pazopanib
por: Mori, Yoshinori, et al.
Publicado: (2018)

Disease Response to Pazopanib in Follicular Dendritic Cell Sarcoma
por: Shah, Pooja, et al.
Publicado: (2020)

Pazopanib in rare histologies of metastatic soft tissue sarcoma
por: Kataria, Babita, et al.
Publicado: (2021)

Treatment of Angiosarcoma with Pazopanib and Paclitaxel: Results of the EVA (Evaluation of Votrient(®) in Angiosarcoma) Phase II Trial of the German Interdisciplinary Sarcoma Group (GISG-06)
por: Pink, Daniel, et al.
Publicado: (2021)

Surrogate endpoints in advanced sarcoma trials: a meta-analysis
por: Savina, Marion, et al.
Publicado: (2018)

A Palette of Fast Simulations in LHCb
por: Whitehead, Mark Peter
Publicado: (2018)

A palette of fast simulations in LHCb
por: Whitehead, Mark Peter
Publicado: (2019)

Choosing color palettes for scientific figures
por: Plante, Timothy B., et al.
Publicado: (2020)

The palette of techniques for cell cycle analysis
por: Eastman, Anna E., et al.
Publicado: (2020)

Relative Dose Intensity of Induction-Phase Pazopanib Treatment of Soft Tissue Sarcoma: Its Relationship with Prognoses of Pazopanib Responders
por: Nakano, Kenji, et al.
Publicado: (2019)

A randomized, double-blind, placebo-controlled, Phase III study of pazopanib in patients with soft tissue sarcoma: results from the Japanese subgroup
por: Kawai, Akira, et al.
Publicado: (2016)

Targeted treatment for advanced soft tissue sarcoma: profile of pazopanib
por: Rajendra, Rajeev, et al.
Publicado: (2013)

Molecular and Pathological Profiling of Corresponding Treatment-Naïve and Neoadjuvant Pazopanib-Treated High-Risk Soft Tissue Sarcoma Samples of the GISG-04/NOPASS Study
por: Gaiser, Timo, et al.
Publicado: (2021)

Treatment patterns and survival in an exhaustive French cohort of pazopanib-eligible patients with metastatic soft tissue sarcoma (STS)
por: Ray-Coquard, Isabelle, et al.
Publicado: (2017)

Neoadjuvant Pazopanib Treatment in High-Risk Soft Tissue Sarcoma: A Quantitative Dynamic (18)F-FDG PET/CT Study of the German Interdisciplinary Sarcoma Group
por: Sachpekidis, Christos, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9c9dh4lehqce9dcf003chbb97q